checkAd

     205  0 Kommentare Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

    MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.

    Late-Breaking Presentations:

    Poster # 2067-LB: Pooled Safety Analysis of Enobosarm from Phase 2 and Phase 3 Placebo-Controlled Clinical Trials

    Highlights from the presentation: In a pooled analysis of 1,027 older men, postmenopausal women, and older patients with advanced cancer, enobosarm was well tolerated with an adverse event profile comparable to the control patients. Notably, there was no increase in gastrointestinal side effects with enobosarm compared to placebo treatment. 3.7% of enobosarm treated subjects versus 1.4% of placebo subjects had elevated alanine transaminase (ALT) levels. In enobosarm treated subjects, these elevations in ALT were transient and mild (grade 1/2) with no evidence of drug induced liver injury by Hy’s Law observed. Cardiovascular adverse event rates were similar between the two groups (less than 2%). The incidence of deep vein thrombosis was higher (3.3%) in the placebo group compared to the enobosarm group (1.0%).

    Poster # 2066-LB: Potential to Optimize Weight Loss with Enobosarm—Meta-analysis of Body Composition from Three Randomized Clinical Trials Support the Ability of Enobosarm to Preserve Muscle while Reducing Fat

    Highlights from the presentation: In meta-analysis of 367 older men, postmenopausal women, and older patients with muscle loss from advanced cancer (clinical studies 501, 502, and 504), enobosarm therapy resulted in reductions in fat mass (-6.26% vs placebo; p=0.006) while preserving lean mass (+4.04% vs placebo; p=0.00007) at day 84. This meta-analysis supports the potential of enobosarm when combined with a GLP-1 receptor agonist to preserve muscle, while preferentially reducing fat to potentially result in a higher quality weight loss in overweight and obese patients.

    Seite 1 von 5


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute …